Novavax: Difference between revisions
CSV import |
CSV import |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Novavax}} | |||
[[File:Novavax-logo.svg|Novavax logo|thumb|right]] | |||
Novavax | |||
'''Novavax, Inc.''' is an American biotechnology company based in [[Gaithersburg, Maryland]]. The company focuses on the development of vaccines to prevent serious infectious diseases. Novavax utilizes innovative technology platforms to create vaccines that are both effective and safe. | |||
Novavax | |||
== | ==History== | ||
Novavax has | Novavax was founded in 1987 and has since been at the forefront of vaccine development. The company initially focused on developing virus-like particle (VLP) vaccines, which mimic the structure of viruses to elicit an immune response without causing disease. | ||
In recent years, Novavax has gained significant attention for its work on vaccines for emerging infectious diseases, including the development of a vaccine for the [[COVID-19 pandemic]]. | |||
Novavax has | |||
== | ==Technology== | ||
Novavax employs a proprietary recombinant nanoparticle technology platform. This platform allows for the creation of stable, highly immunogenic nanoparticles that can be used to develop vaccines against a variety of infectious diseases. | |||
The company's technology is designed to produce vaccines that are both effective and easy to manufacture at scale, making them suitable for rapid deployment in response to pandemics. | |||
==COVID-19 Vaccine== | |||
[[File:Novavax_Building.jpg|Novavax Building|thumb|left]] | |||
During the COVID-19 pandemic, Novavax developed a vaccine candidate known as NVX-CoV2373. This vaccine is based on the company's recombinant nanoparticle technology and includes an adjuvant to enhance the immune response. | |||
NVX-CoV2373 has undergone extensive clinical trials and has shown high efficacy in preventing COVID-19 infection. The vaccine has been authorized for emergency use in several countries and is part of global vaccination efforts. | |||
==Research and Development== | |||
[[File:Novavax_research_and_development.jpg|Novavax Research and Development|thumb|right]] | |||
Novavax continues to invest in research and development to expand its vaccine portfolio. The company is exploring vaccines for other infectious diseases, including influenza, respiratory syncytial virus (RSV), and Ebola. | |||
The company's R&D efforts are supported by collaborations with various government agencies and international organizations, which provide funding and resources to accelerate vaccine development. | |||
==Corporate Structure== | |||
Novavax is led by a team of experienced executives and scientists. The company's headquarters are located in Gaithersburg, Maryland, with additional facilities dedicated to research, development, and manufacturing. | |||
==Community and Global Impact== | |||
[[File:Larry_Hogan_at_Novavax_campus_(51239176189).jpg|Larry Hogan at Novavax campus|thumb|left]] | |||
Novavax is committed to improving global health by providing access to life-saving vaccines. The company collaborates with international health organizations to ensure that its vaccines reach populations in need, particularly in low- and middle-income countries. | |||
==Related Pages== | |||
* [[Biotechnology]] | |||
* [[Vaccine]] | * [[Vaccine]] | ||
* [[COVID-19]] | * [[COVID-19 pandemic]] | ||
* [[ | * [[Virus-like particle]] | ||
[[Category: | {{Biotechnology companies of the United States}} | ||
{{COVID-19 pandemic}} | |||
[[Category:Biotechnology companies of the United States]] | |||
[[Category:Vaccine producers]] | [[Category:Vaccine producers]] | ||
[[Category:Companies based in Maryland]] | [[Category:Companies based in Maryland]] | ||
[[Category: | [[Category:COVID-19 pandemic]] | ||
Latest revision as of 18:53, 23 March 2025
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland. The company focuses on the development of vaccines to prevent serious infectious diseases. Novavax utilizes innovative technology platforms to create vaccines that are both effective and safe.
History[edit]
Novavax was founded in 1987 and has since been at the forefront of vaccine development. The company initially focused on developing virus-like particle (VLP) vaccines, which mimic the structure of viruses to elicit an immune response without causing disease.
In recent years, Novavax has gained significant attention for its work on vaccines for emerging infectious diseases, including the development of a vaccine for the COVID-19 pandemic.
Technology[edit]
Novavax employs a proprietary recombinant nanoparticle technology platform. This platform allows for the creation of stable, highly immunogenic nanoparticles that can be used to develop vaccines against a variety of infectious diseases.
The company's technology is designed to produce vaccines that are both effective and easy to manufacture at scale, making them suitable for rapid deployment in response to pandemics.
COVID-19 Vaccine[edit]
During the COVID-19 pandemic, Novavax developed a vaccine candidate known as NVX-CoV2373. This vaccine is based on the company's recombinant nanoparticle technology and includes an adjuvant to enhance the immune response.
NVX-CoV2373 has undergone extensive clinical trials and has shown high efficacy in preventing COVID-19 infection. The vaccine has been authorized for emergency use in several countries and is part of global vaccination efforts.
Research and Development[edit]
Novavax continues to invest in research and development to expand its vaccine portfolio. The company is exploring vaccines for other infectious diseases, including influenza, respiratory syncytial virus (RSV), and Ebola.
The company's R&D efforts are supported by collaborations with various government agencies and international organizations, which provide funding and resources to accelerate vaccine development.
Corporate Structure[edit]
Novavax is led by a team of experienced executives and scientists. The company's headquarters are located in Gaithersburg, Maryland, with additional facilities dedicated to research, development, and manufacturing.
Community and Global Impact[edit]
.jpg)
Novavax is committed to improving global health by providing access to life-saving vaccines. The company collaborates with international health organizations to ensure that its vaccines reach populations in need, particularly in low- and middle-income countries.
